Added to YB: 2025-01-02
Pitch date: 2024-12-30
NVO [bullish]
Novo Nordisk A/S
-55.12%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 81.71
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Show full summary:
10 Stocks to watch in 2025 - Novo Nordisk A/S
NVO: Ozempic & Wegovy drive stock surge. Only competitor is Eli Lilly. 2-year manufacturing lead. Novo Nordisk Foundation majority shareholder ensures long-term focus, takeover protection. Strong market position in weight loss drugs, potential for continued growth.
Read full article (1 min)